SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025)

Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. As a result of the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages. In recent years, locoregional and systemic therapies have increasingly been directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit. New therapeutic strategies, such as immunotherapy, targeted drugs, and antibody-drug conjugates, have also improved outcomes in some patient subgroups. This clinical practice guideline for early-stage breast cancer (updated in 2025) is based on a systematic review of relevant studies and on the consensus of experts from the Spanish Breast Cancer Research Group (GEICAM), Spanish Collaborative Group for the Study, Treatment and Other Experimental Strategies in Solid Tumors (SOLTI), and Spanish Society of Medical Oncology (SEOM).

Authors

Institutions

Publication Details

Journal
Clinical & Translational Oncology
Published
2025-11-29
DOI
https://doi.org/10.1007/s12094-025-04139-x
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025)

María Vidal, Francisco Ayala, Joaquín Gavilá Gregori, Lucía González Cortijo et al.
Clinical & Translational Oncology
Breast Cancer Treatment Studies
article

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025)

María Vidal, Francisco Ayala, Joaquín Gavilá Gregori, Lucía González Cortijo, Cristina Morales Estévez, Silvia Antolín, Agostina Stradella, Fernando Henao, Eva Ciruelos, María Teresa Martínez
article en

Abstract

Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. As a result of the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages. In recent years, locoregional and systemic therapies have increasingly been directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit. New therapeutic strategies, such as immunotherapy, targeted drugs, and antibody-drug conjugates, have also improved outcomes in some patient subgroups. This clinical practice guideline for early-stage breast cancer (updated in 2025) is based on a systematic review of relevant studies and on the consensus of experts from the Spanish Breast Cancer Research Group (GEICAM), Spanish Collaborative Group for the Study, Treatment and Other Experimental Strategies in Solid Tumors (SOLTI), and Spanish Society of Medical Oncology (SEOM).

Clinical & Translational OncologyVol. 28(1)
Hospital General Universitario Gregorio Marañón (ES), Research Institute Hospital 12 de Octubre (ES), Hospital Universitario Virgen Macarena (ES), Fundación Instituto Valenciano de Oncología (ES), Institut Català d'Oncologia (ES), Hospital Universitario Quirónsalud Madrid (ES), Hospital Clínic de Barcelona (ES), HM Hospitales (ES), Hospital Universitario Reina Sofía (ES), Complexo Hospitalario Universitario A Coruña (ES), INCLIVA Health Research Institute (ES)
Sociedad Española de Oncología Médica
Openalex Percentile: Top 54%
Breast Cancer Treatment Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.